Worried about your State Pension income? Here are 2 FTSE 100 dividend stocks I’d buy today

These two FTSE 100 (INDEXFTSE:UKX) stocks could deliver improving income returns in my opinion.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the State Pension amounting to just £8,767 per year, many retirees are likely to need a second income in older age.

Since the FTSE 100 appears to offer good value for money at the present time, with it having a dividend yield of around 4.5%, there are a number of opportunities to generate a growing passive income across the large-cap share universe.

With that in mind, here are two FTSE 100 stocks that could offer an improving income outlook, as well as relatively stable financial performance over the long term.

AstraZeneca

It’s been a difficult journey for pharmaceutical company AstraZeneca (LSE: AZN) over the last decade. It has seen its profitability fall heavily due to the loss of patents on key drugs, with this leading to a lack of dividend growth in recent years.

Now though, the company appears to be in a relatively strong position. It has invested heavily in its pipeline under a strategy that has sought to focus on core growth areas. This strategy is now expected to bear fruit, with the business forecast to post a rise in net profit of around 12% in the current year.

This could stimulate AstraZeneca’s dividend growth prospects, and lead to an improving income outlook for its investors. It now has a dividend yield of just 3.4%, but its potential to increase dividends at a pace that exceeds inflation could lead to a robust outlook from an income perspective.

Alongside this, the company’s defensive appeal could help it to outperform the wider FTSE 100 at a time when the prospects for the global economy remain highly uncertain.

Unilever

Unilever’s (LSE: ULVR) recent updates have shown that its current growth strategy is paying off. It has focused investment on fast-growing markets across the emerging world, with them now making up the lion’s share of its revenue. They are also the main catalyst behind the company’s growth rate, and are likely to remain so over the medium term as wages in countries such as China move higher at a rapid rate.

Like AstraZeneca, Unilever’s dividend yield is below that of the wider FTSE 100 at the present time. The consumer goods company is set to record an income return of just 2.9% in the current year. However, with its bottom line forecast to produce a gain of 10% this year and its dividend payments being covered 1.6 times by profit, the scope for a rapidly-rising dividend seems to be high.

Although Unilever may lack the defensive appeal of some of its FTSE 100 peers, its potential to enjoy above-average growth over the long run seems to be high. It has a wide range of popular brands in a number of different markets. This provides it with a wide economic moat which, alongside its growth potential, makes it an enticing income opportunity for the long term.

Peter Stephens owns shares of AstraZeneca and Unilever. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »